Surprisingly an anti-BCL2 targeted approach towards hMB lymphoma cells, using the BCL2 inhibitor ABT-737, also failed to promote lymphoma cell apoptosis (Supplementary Figure S4).
This humanized mouse model of 'double-hit' lymphoma allowed us to assess the efficacy of human-specific antibody-based therapeutics.